Correlation between the Her-2/neu status as determined by immunohistochemical analysis and the serum Her-2/neu concentration as determined by the use of ADVIA Cencaur® automated immunoassay in breast cancer patients

Journal of Breast Cancer

Volumn 11, Issue 3, 2008, Pages 116-124

  Lee, Jung Sun ^a   Won, Ki Min ^a   Eun, Hwa Park ^a   Lim, Woo Sung ^a   Choi, Sung Lim ^a   Son, Byung Ho ^a   Kim, Sung Bae ^a   Ahn, Jin Hee ^a   Ahn, Sei Hyun ^a  

^a University of Ulsan   (South Korea)

Author keywords

Breast cancer; Her 2 neu; Immunohistochemisty

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CHEMOLUMINESCENCE; FEMALE; FLUORESCENCE; HORMONE RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; KOREA; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TUMOR VOLUME;

EID: 70350604159     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2008.11.3.116     Document Type: Article

References (27)

1. Ross JS, Fletcher JA. The Her-2/neu oncogene in breast cancer: prognostic factor, predicitve factor, and target for therapy. Stem Cell 1998;16:413-428 (Pubitemid 28524507)
2. Lal P, Salazar PA, Hudis CA, Ladanyi M, Chen B. Her-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization. Am J Clin Pathol 2004;121:631-636
3. Schaller G, Evers K, Papadopoulos S, Ebert A, Buhler H. Current use of Her2 test. Ann Oncol 2001;12:S97-100.
4. Narita T, Funahashi H, Satoh Y, Takashi H. C-erbB2 protein in sera of breast cancer patients. Breast Cancer Res Treat 1992;24:97-102. (Pubitemid 23063892)
5. Ali SA, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, et al. Relationship of serum Her-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 2002;48:1314-1320 (Pubitemid 34809841)
6. Harris LN, Liotcheva V, Broadwater G, Ramirez MJ, Maimonis P, Anderson S, et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001;19:1698-1706 (Pubitemid 32230870)
7. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer. Clin Cancer Res 2001;7:2703-2711
8. Yamauchi H, O'Neil A, Gelman R, Carney W, Tenny D, Hosch S, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracelluar domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518-2525 (Pubitemid 27289880)
9. Classen S, Kopp R, Possinger K, Weidenhagen R, Eiermann W, Wilmanns W. Clinical relevance of soluble c-erbB2 for patients with metastatic breast cancer predicting the response to second line hormone or chemotherapy. Tumor Biol 2002;23:70-75 (Pubitemid 34639108)
10. Muller V, Witzel I, Pantel K, Krenkel S, Luck HJ, Neumann R, et al. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res 2006;26:1479-1487
11. Mehta RR, McDermott JH, Heiken TJ, Marler KC, Patel MK, Wild LD, et al. Plasma c-erbB2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998;16:2409-2491
12. Schoendorf T, Hoopmann M, Warm M, Neumann R, Thomas A, Gohring UJ, et al. Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastasis receiving trastuzumab therapy predict the clinical course. Clin Chem 2002;48:1360-1362 (Pubitemid 34809846)
13. Hoopmann M, Neumann R, Tanasale T, Schondorf T, HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastatic breast cancer; a longitudinal study. Anticancer Res 2003;23:1031-1034 (Pubitemid 36750915)
14. Isola JJ, Holli K, Oksa H, Teramato Y, Kallioniemi OP. Elevated erbB2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994;73:652-658 (Pubitemid 24046607)
15. Kim JW, Kim SY, Lee HS, Woo HD, Son DM, Lim CW, et al. Establishment for reference range of serum Her-2/neu in Korean healthy women. J Breast Cancer 2006;9:301-308
16. Kong SY, Kang JH, Kwon Y, Kang HS, Chung KW, Kang SH, et al. Serum Her-3 concentration in patient with primary breast cancer. J Clin Pathol 2006;59:373-376
17. Watanabe N, Miyamoto Y, Tokuda Y, Kubota M, Ando Y, Tajima T, et al. Serum c-erbB2 in breast cancer patients . Acta Oncol 1994;33:901-904
18. Carney WP, Neumann DR, Lipton A, Leitzel K, Ali S, Price CP. Potential clinical utility of serum Her-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 2003;49:1579-1598 (Pubitemid 37194212)
19. Cook GB, Neaman IE, Goldblatt JL, Cambetas DR, Hussain M, Luftner D, et al. Clinial utility of serum Her-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 2001;21:1465-1470 (Pubitemid 32494167)
20. Brandt-Rauf PW, Pincus MR, Carney WP. The c-erbB2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog 1994;5:313-329
21. Isola JJ, Holli K, Okasa H, Teramoto Y, Kallioniemi OP. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994;73:652-658 (Pubitemid 24046607)
22. Willsher PC, Beaver J, Pinder S, Bell JA, Ellis EO, Blamey RW, et al. Prognostic significance of serum c-erbB2 protein in breast cancer patients. Breast Cancer Res Treat 1996;40:251-255 (Pubitemid 26336120)
23. Kostler WJ, Schwab B, Singer CF, Neumann R, Rucklinger E, Brodowicz T, et al. Monitoring of serum HER-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 2004;10:1618-1624 (Pubitemid 38435551)
24. Molina R, J Jo, Zanon G, Filella X, Farrus B, Munoz M, et al. Utility of C-erbB2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer 1996;74:1126-1131 (Pubitemid 26333918)
25. Anderson TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL. Detection of c-erbB2 related protein in sera from breast cancer patients. Acta Oncologica 1995;34:499-504.
26. Imoto S, Kitoh T, Hasebe T. Serum c-erbB2 levels in monitoring operable breast cancer. Jpn J Clin Oncol 1999;29:336-339
27. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, et al. C-erb B2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Anticancer Res 1996;16:2295-2300